The FDA has greenlit pembrolizumab, marking a significant shift in the landscape of head and neck cancer (HNSCC) treatment. This approval offers new hope for patients with resectable cancers, providing a novel therapeutic avenue. the decision, rooted in the promising results of the KEYNOTE-689 trial, spotlights the drug’s potential in improving event-free survival.Pembrolizumab’s approved request includes use before and after surgery, frequently enough combined with radiation and, potentially, cisplatin. The news underscores the critical role of advancements in cancer care, offering hope and enhanced treatment options. News Directory 3 delivers the latest on this breakthrough. Discover what’s next …
FDA Approves Pembrolizumab for Head and Neck Cancer Treatment
The Food and Drug administration (FDA) has approved pembrolizumab (keytruda, Merck) for adult patients with resectable